Pain management in the 21st century: utilization of pharmacogenomics and therapeutic drug monitoring

Bibliography

• World Health Organization. Cancer pain relief and palliative care. Technical report series No 804. WHO, Geneva; 1990
   Google Scholar
• Hanks GW, Conno F, Cherny N, Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-93
   PubMed Web of Science ®Google Scholar
• Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91
   PubMed Web of Science ®Google Scholar
• White S, Wong SHY. Standards of laboratory practice: analgesic drug monitoring. Clin Chem 1998; 44:1110-23
   PubMed Web of Science ®Google Scholar
• Lotsch J, Von Hentig N, Freynhagen R, Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers. Pharmacogenet Genomics 2009;19:429-36
   PubMed Web of Science ®Google Scholar
• Jannetto PJ, Bratanow NC. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management. Pharmacogenomcis 2009;10(7):1157-67
   PubMed Web of Science ®Google Scholar
• Kosarac B, Fox AA, Collard CD. Effect of genetic factors on opioid action. Curr Opin in Anesth 2009;22:476-82
   PubMed Web of Science ®Google Scholar
• Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin. Pharmacol Ther 2007;81(3):429-44
   Web of Science ®Google Scholar
• Smith HS. Variations in opioid responsiveness. Pain Physician 2008;11(2):237-48
   PubMed Web of Science ®Google Scholar
• Campa D, Gioia A, Tomei A, Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008;83:559-66
   PubMed Web of Science ®Google Scholar
• Levran O, O'Hara K, Peles E, ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 2008;17:2219-27
   PubMed Web of Science ®Google Scholar
• Crettol S, Deglon JJ, Besson J, No influence of ABCB1 haplotypes on methadone dosage requirement. Clin Pharmacol Ther 2008;83:668-9
   PubMed Web of Science ®Google Scholar
• Kirchheimer J, Schmidt H, Tzvetkow M, Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics 2007;7:257-65
   Web of Science ®Google Scholar
• Poulsen L, Arendt-Nielsen L, Brosen K, The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996;60:636-44
   PubMed Web of Science ®Google Scholar
• Lotsch J, Skarke C, Liefhold J, Genetic predictors of the clinical response to opioid analgesics: clinical utility and future prospective. Clin Pharmacokinet 2004;43(14):983-1013
   PubMed Web of Science ®Google Scholar
• Stamer UM, Stuber F. The pharmacogenetics of analgesia. Expert Opin Pharmacother 2007;8:2235-45
   PubMed Web of Science ®Google Scholar
• Chou WY, Yang LC, Lu HF, Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand 2006;105:334-7
   Google Scholar
• Chou WY, Wang CH, Liu PH, Candidate gene polymorphisms predicting individual sensitivity to opioids. Naunyn Schmiedebergs Arch Pharmacol 2008;377:269-81
   PubMed Web of Science ®Google Scholar
• Hayashida M, Nagashima M, Satoh Y, Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics 2008;9:1605-16
   PubMed Web of Science ®Google Scholar
• Landau R, Kern C, Columb MO, Genetic variability of the µ-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain 2008:139:5-14
   PubMed Web of Science ®Google Scholar
• Sia AT, Lim Y, Lim ECP, A118G single nucleotide polymorphism of human µ-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology 2008;109:520-6
   PubMed Web of Science ®Google Scholar
• Walter C, Lotsch J. Meta-analysis of the relevance of OPRM1 118A > G genetic variant for pain treatment. Pain 2009;146:270-5
   PubMed Web of Science ®Google Scholar
• Lotta T, Vidgren J, Tilgmann C, Kinetics of human soluble and membrane bound catechol O-demethyltransferase: a revised mechanism and description of the thermoliable variant of the enzyme. Biochemistry 1995;34:4202-10
   PubMed Web of Science ®Google Scholar
• Rakvag TT, Klepstad P, Baar C, The Val58Met polymorphism of the human catechol O-demethyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 2005;116:73-8
   PubMed Web of Science ®Google Scholar
• Rakvag TT, Ross JR, Sato H, Genetic variation in the catechol-O-Methyltransferase (COMT) gene and morphine requirements in cancer patients with pain. Mol Pain 2008;4:64-76
   PubMed Web of Science ®Google Scholar
• Gourlay DL, Heit HA, Caplan YH. Urine drug testing in clinical practice, dispelling the myths and designing strategies. 3rd edition. PharmaCom Group, Stamford, CT; 2006. p. 1-28
   Google Scholar
• Nafziger AN, Bertino JS. Utility and application of urine drug testing in chronic pain management with opioids. Clin J Pain 2009;25(1):73-9
   PubMed Web of Science ®Google Scholar
• Ceder G, Jones AW. Concentration ratios of morphine to codeine in blood of impaired drivers as evidence of heroin use and not medication with codeine. Clin Chem 2001;47:1980-4
   PubMed Web of Science ®Google Scholar
• Reyes-Gibby CC, Shete S, Rakvag T, Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 2007;130(1-2):25-30
   PubMed Web of Science ®Google Scholar
• Argoff CE. Clinical implications of opioid pharmacogenetics. Clin J Pain 2010;10:S16-20
   Web of Science ®Google Scholar
• Jin M, Gock SB, Jannetto PJ, Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A4*1B and 3A5*3 for 25 fentanyl cases. J Anal Toxicol 2002;26(7):438-47
   PubMed Web of Science ®Google Scholar
• Jannetto PJ, Wong SH, Gock SB, Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping chytochrome P450 2D6 for oxycodone cases. J Anal Toxicol 2002;26(7):438-47
   PubMed Web of Science ®Google Scholar
• Mrazek DA. Psychiatric pharmacogenomic testing in clinical practice. Dialogues Clin Neurosci 2010;12(1):69-76
   PubMedGoogle Scholar
• Chung WH, Hung SI, Hong HS, Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004;428(6982):486
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA public health advisory: use of codeine by some breastfeeding mothers may lead to life-threatening side effects in nursing babies. Available from: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/acm054717.htm [Last accessed 17 April 2009]
   Google Scholar
• Wong SH, Happy C, Blinka D, From personalized medicine to personalized justice: the promise of translational pharmacogenomics in the justice system. Pharmacogenomics 2010;11(6):731-7
   PubMed Web of Science ®Google Scholar
• Rettie AE, Tai G. The pharmacogenomics of warfarin: closing in on personalized medicine. Mol Interv 2006;6(4):223-7
   PubMed Web of Science ®Google Scholar
• McLean LA, Gathmann I, Capdeville R, Pharmacogenetic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib. Clin Cancer Res 2004;10(1):155-65
   PubMed Web of Science ®Google Scholar
• Thervet E, Anglicheau D, King B, Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003;76(8):1233-5
   PubMed Web of Science ®Google Scholar
• Abeles AM, Pillinger MH, Solitar BM, Narrative review: the pathophysiology of fibromyalgia. Ann Intern Med 2007;146:726-34
   PubMed Web of Science ®Google Scholar
• Guersoy S, Erdal E, Herken H, Association of T102C polymorphism of the 5-HT2A receptor gene with psychiatric status in fibromyalgia syndrome. Rheumatol Int 2001;21(2):58-61
   PubMed Web of Science ®Google Scholar
• Bazzichi L, Giannaccini G, Betti L, Alteration of serotonin transporter density and activity in fibromyalgia. Arthritis Res Ther 2006;8(4):R99
   PubMed Web of Science ®Google Scholar
• Cohen H, Buskila D, Neumann L, Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5- HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum 2002;46(3):845-7
   PubMed Web of Science ®Google Scholar
• D Buskila D, Cohen H, Neumann L, An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 2004;9:730-1
   PubMed Web of Science ®Google Scholar
• Guersoy S, Erdal E, Herken Hasan, Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int 2003;23(3):104-7
   PubMed Web of Science ®Google Scholar
• Zubieta JK, Heitzeg MM, Smith YR, COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science 2003;299(5610):1240-3
   PubMed Web of Science ®Google Scholar
• Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie 2003;58:447-74
   PubMed Web of Science ®Google Scholar
• Jannetto PJ, Bratanow NC. Pharmacogenomic considerations in the opioid management of pain. Genome Med 2010;2:66
   PubMed Web of Science ®Google Scholar